<DOC>
	<DOC>NCT03100344</DOC>
	<brief_summary>The aim of the study is to assess the efficacy of multiple subcutaneous dose of nemolizumab administrated concomitantly with Topical Corticosteroids, in moderate to severe atopic dermatitis subjects with severe pruritus who were not adequately controlled with topical treatment.</brief_summary>
	<brief_title>Dose-ranging Study of Nemolizumab in Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male or female subjects ≥ 18 years (or legal age when higher) Chronic AD, that has been present for at least 2 years before the visit Eczema Area and Severity Index (EASI) score ≥12 IGA score ≥ 3 AD involvement ≥ 10% of Body Surface Area (BSA) Severe pruritus on at least 3 of the last 7 days before the visit Documented recent history (within 6 months before the visit) of inadequate response to topical medications Female subjects must fulfill one of the criteria below: Female subjects of nonchildbearing potential Female subjects of childbearing potential who agree to a true abstinence or to use an effective or highly effective method of contraception throughout the clinical trial and for 120 days after the last study drug administration Body weight &lt; 45 kg subjects with a medical history of asthma requiring hospitalization in the last 12 months before screening visit and/or whose asthma has not been wellcontrolled during the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) &lt;80% of the predicted value Cutaneous bacterial or viral infection within 1 week before the screening visit or during the runin period Infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit or during the runin period Requiring rescue therapy during the runin period, or expected to require rescue shortly following the baseline visit Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb], hepatitis C antibody or Human Immunodeficiency virus [HIV] antibody) at the screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>